Jiangsu Jibeier Pharmaceutical Future Growth
Future criteria checks 4/6
Jiangsu Jibeier Pharmaceutical is forecast to grow earnings and revenue by 23.7% and 23.2% per annum respectively. EPS is expected to grow by 23.5% per annum. Return on equity is forecast to be 14.5% in 3 years.
Key information
23.7%
Earnings growth rate
23.5%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 23.2% |
| Future return on equity | 14.5% |
| Analyst coverage | Low |
| Last updated | 02 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,549 | 414 | N/A | 391 | 2 |
| 12/31/2025 | 1,277 | 335 | N/A | 336 | 2 |
| 12/31/2024 | 1,051 | 272 | N/A | 484 | 2 |
| 9/30/2024 | 887 | 239 | 4 | 234 | N/A |
| 6/30/2024 | 876 | 245 | -77 | 181 | N/A |
| 3/31/2024 | 890 | 234 | -148 | 139 | N/A |
| 12/31/2023 | 861 | 219 | -198 | 160 | N/A |
| 9/30/2023 | 845 | 230 | -211 | 143 | N/A |
| 6/30/2023 | 816 | 209 | -187 | 194 | N/A |
| 3/31/2023 | 681 | 164 | -104 | 236 | N/A |
| 12/31/2022 | 655 | 155 | -142 | 151 | N/A |
| 9/30/2022 | 569 | 118 | -84 | 155 | N/A |
| 6/30/2022 | 516 | 101 | -4 | 161 | N/A |
| 3/31/2022 | 528 | 117 | 8 | 149 | N/A |
| 12/31/2021 | 510 | 115 | 67 | 151 | N/A |
| 9/30/2021 | 530 | 127 | 87 | 130 | N/A |
| 6/30/2021 | 574 | 140 | 94 | 130 | N/A |
| 3/31/2021 | 570 | 132 | 93 | 114 | N/A |
| 12/31/2020 | 566 | 130 | 94 | 117 | N/A |
| 9/30/2020 | 543 | 118 | 112 | 142 | N/A |
| 6/30/2020 | 530 | 110 | 85 | 117 | N/A |
| 3/31/2020 | 531 | 114 | 80 | 117 | N/A |
| 12/31/2019 | 543 | 113 | 85 | 115 | N/A |
| 12/31/2018 | 485 | 97 | 90 | 98 | N/A |
| 12/31/2017 | 452 | 78 | N/A | 112 | N/A |
| 12/31/2016 | 444 | 77 | N/A | 39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688566's forecast earnings growth (23.7% per year) is above the savings rate (2.8%).
Earnings vs Market: 688566's earnings (23.7% per year) are forecast to grow slower than the CN market (26.1% per year).
High Growth Earnings: 688566's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688566's revenue (23.2% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688566's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688566's Return on Equity is forecast to be low in 3 years time (14.5%).